KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Other Non Operating Income: 2015-2025

Historic Other Non Operating Income for BeOne Medicines (ONC) over the last 10 years, with Sep 2025 value amounting to -$19.0 million.

  • BeOne Medicines' Other Non Operating Income fell 267.69% to -$19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.6 million, marking a year-over-year decrease of 215.42%. This contributed to the annual value of -$12.6 million for FY2024, which is 104.10% down from last year.
  • Per BeOne Medicines' latest filing, its Other Non Operating Income stood at -$19.0 million for Q3 2025, which was down 332.39% from $8.2 million recorded in Q2 2025.
  • BeOne Medicines' 5-year Other Non Operating Income high stood at $336.7 million for Q3 2023, and its period low was -$800.2 million during Q4 2021.
  • Moreover, its 3-year median value for Other Non Operating Income was $4.0 million (2025), whereas its average is $26.2 million.
  • Per our database at Business Quant, BeOne Medicines' Other Non Operating Income skyrocketed by 451.16% in 2021 and then slumped by 14,850.06% in 2022.
  • BeOne Medicines' Other Non Operating Income (Quarterly) stood at -$800.2 million in 2021, then skyrocketed by 102.43% to $19.4 million in 2022, then declined by 13.83% to $16.7 million in 2023, then plummeted by 182.00% to -$13.7 million in 2024, then slumped by 267.69% to -$19.0 million in 2025.
  • Its last three reported values are -$19.0 million in Q3 2025, $8.2 million for Q2 2025, and $4.0 million during Q1 2025.